Sign inJoin waitlistJoin the waitlist

Petros Grivas

Medical Director, Local/Regional Outreach, Fred Hutch · University of Washington School of Medicine

Credentials: · · · · · · ·

History

Local/Regional Outreach · University of Washington School of Medicine
Present
International Program · University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

Hematology and Medical Oncology
University of Michigan
2008–2011
Drexel University College of Medicine/Hahnemann University
2005–2008
Doctor of Medicine
2001–2005

Research

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm,…
The Lancet · 2016 · 2,972 citations
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
The Lancet · 2017 · 1,812 citations
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
The Lancet · 2020 · 1,345 citations

Evan Yu
56 papers
Shilpa Gupta
49 papers
Ali Khaki
48 papers · 9 as a fellow
Jonathan Wright
47 papers
Joaquim Bellmunt
44 papers
Vadim Koshkin
40 papers · 13 as a fellow
Neeraj Agarwal
37 papers
GS
Guru Sonpavde
35 papers
Ashish Kamat
32 papers
PS
Philippe Spiess
32 papers
Matthew Galsky
31 papers
Robert Montgomery
31 papers

Clinical trials

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
Principal investigator · Terminated · Phase 2
University of Washington
2023–2026
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
Principal investigator · Completed · Phase 2
University of Washington
2020–2025
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Study chair · Completed · Phase 1
PrECOG, LLC.
2019–2022
Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma
Study chair · Completed
AstraZeneca
2019–2023